BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• Business

  cTRL Therapeutics Appoints Ruben Rodriguez, Ph.D., as Head of Research

  cTRL Therapeutics today announced the appointment of Ruben Rodriguez , Ph.D., as Head of Research.

  December 12, 2023

   · 

  3 min read
• BioCapital

  AbelZeta Presents Data from Two Clinical Studies Relating to its Immuno-Oncology Drug Development at the 65th ASH Annual Meeting

  AbelZeta Pharma presented clinical data for both C-CAR039 for the treatment of patients with relapsed or refractory (r/r) B-cell non-Hodgkin lymphoma (B-NHL).

  December 12, 2023

   · 

  7 min read
• BioCapital

  Incyte to Present at Upcoming Investor Conferences - December 12, 2023

  Incyte (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of January.

  December 12, 2023

   · 

  1 min read
• Drug Development

  Obsidian Therapeutics Announces Positive Interim Top-Line Clinical Data for OBX-115 Engineered TIL Cell Therapy in Advanced or Metastatic Melanoma Post-Anti-PD1 Therapy

  Obsidian Therapeutics, Inc. announced today positive top-line results from the ongoing first-in-human, Phase 1 clinical trial evaluating the safety and efficacy of OBX-115.

  December 12, 2023

   · 

  4 min read
• Vivasure Medical Announces First Patients Treated with PerQseal Elite Closure Device System

  Vivasure Medical today announced the first patient treated with PerQseal ® Elite, the latest generation of the company’s fully absorbable large-hole closure system.

  December 12, 2023

   · 

  3 min read
• Genetown

  Moderna Announces Changes to Commercial Organization to Prepare for Multiple Product Launches in 2024 and 2025

  Moderna, Inc. (NASDAQ:MRNA) today announced changes to its operating model to bring focus to its short- and long-term business goals.

  December 12, 2023

   · 

  3 min read
• MolecuLight Successfully Completes SOC 2 Type II Audit

  MolecuLight Inc., the leader in point-of-care fluorescence imaging that locates and detects elevated bacterial loads in and around wounds, announces that it successfully completed its Service Organization Control 2 Type II audit.

  December 12, 2023

   · 

  3 min read
• Business

  C4 Therapeutics Announces License and Research Collaboration with Merck to Discover and Develop Degrader-Antibody Conjugates (DACs)

  C4 Therapeutics, Inc. today announced that it has entered into an exclusive license and collaboration agreement with Merck to develop degrader-antibody conjugates (DACs).

  December 12, 2023

   · 

  4 min read
• Deals

  RedHill Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement - December 12, 2023

  RedHill Biopharma Ltd. today announced that it received confirmation from The Nasdaq Stock Market LLC (“Nasdaq”) that it had regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5450(a)(1).

  December 12, 2023

   · 

  7 min read
• Business

  ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2023

  ESSA Pharma Inc. (“ESSA”, or the “Company”) (NASDAQ: EPIX), a clinical-stage pharmaceutical company, focused on developing novel therapies for the treatment of prostate cancer, today provided a corporate update and reported financial results for the fourth quarter and fiscal year ended September 30, 2023.

  December 12, 2023

   · 

  11 min read